Isoelectric focusing patterns of beta-lactamases in the rapidly growing mycobacteria.

[1]  T Ezaki,et al.  Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. , 1992, International journal of systematic bacteriology.

[2]  R. Wallace,,et al.  beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis. , 1992, The American review of respiratory disease.

[3]  R. Wallace,,et al.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid , 1991, Antimicrobial Agents and Chemotherapy.

[4]  R. Wallace,,et al.  Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. , 1991, The Journal of infectious diseases.

[5]  J. Kilburn,et al.  High-performance liquid chromatography patterns of mycolic acids as criteria for identification of Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium smegmatis , 1990, Journal of clinical microbiology.

[6]  D. Denning,et al.  Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. , 1989, Reviews of infectious diseases.

[7]  Nalin Rastogi,et al.  Isoenzymes as tools to discriminate various subdivisions in the Mycobacterium fortuitum complex. , 1989, Acta leprologica.

[8]  M. Cynamon,et al.  In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid. , 1988, The Journal of antimicrobial chemotherapy.

[9]  S. Huovinen.  Rapid isoelectric focusing of plasmid-mediated beta-lactamases with Pharmacia PhastSystem , 1988, Antimicrobial Agents and Chemotherapy.

[10]  R. Wallace,,et al.  Human disease due to Mycobacterium smegmatis. , 1988, The Journal of infectious diseases.

[11]  J. McCormack,et al.  Bacteremia caused by Mycobacterium neoaurum , 1988, Journal of clinical microbiology.

[12]  R. Wallace,,et al.  Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae , 1987, Journal of clinical microbiology.

[13]  M. Cynamon,et al.  Comparison of four β-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis , 1987 .

[14]  P. Leuenberger,et al.  [Pleuropulmonary infection caused by Mycobacterium smegmatis. Case description and literature review]. , 1986, Schweizerische medizinische Wochenschrift.

[15]  R. Wallace,,et al.  Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility. , 1986, The American review of respiratory disease.

[16]  F. Grimont,et al.  Deoxyribonucleic Acid Relatedness Study of the Mycobacterium fortuitum-Mycobacterium chelonae Complex , 1986 .

[17]  C Thornsberry,et al.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.

[18]  R. Wallace,,et al.  Isoelectric focusing of beta-lactamases in Mycobacterium fortuitum. Association of a single enzyme pattern with cefoxitin resistance. , 1985, The American review of respiratory disease.

[19]  D. N. Wright,et al.  Mycobacterium thermoresistibile infection in an immunocompromised host , 1984, Journal of clinical microbiology.

[20]  R. Wallace,,et al.  Bacteremia caused by a previously unidentified species of rapidly growing Mycobacterium successfully treated with vancomycin. , 1983, Annals of internal medicine.

[21]  M. Cynamon,et al.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis , 1983, Antimicrobial Agents and Chemotherapy.

[22]  R. Good,et al.  Spectrum of disease due to rapidly growing mycobacteria. , 1983, Reviews of infectious diseases.

[23]  H. Lode,et al.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam , 1983, Antimicrobial Agents and Chemotherapy.

[24]  C. Thornsberry,et al.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution , 1982, Antimicrobial Agents and Chemotherapy.

[25]  R. Good,et al.  Peritonitis due to a mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis. , 1982, The Journal of infectious diseases.

[26]  G. W. Ross,et al.  Isoelectric focusing studies on Mycobacterium chelonei. , 1981, Tubercle.

[27]  R. Good,et al.  Identification of clinically significant Mycobacterium fortuitum complex isolates , 1981, Journal of clinical microbiology.

[28]  M. Corrado,et al.  Mycobacterium thermoresistibile: a new pathogen for humans , 1981, Journal of clinical microbiology.

[29]  I. Phillips,et al.  Isoelectric focusing of Bacteroides melaninogenicus group beta-lactamases , 1981, Antimicrobial Agents and Chemotherapy.

[30]  M. Cynamon,et al.  In vitro susceptibility of Mycobacterium fortuitum to cefoxitin , 1981, Antimicrobial Agents and Chemotherapy.

[31]  R. Labia,et al.  Beta-Lactamases: Determination of Their Isoelectric Points , 1978, Antimicrobial Agents and Chemotherapy.

[32]  R. Sykes,et al.  The -lactamases of Gram-negative bacteria and their rle in resistance to -lactam antibiotics , 1976 .

[33]  M. Ridell,et al.  A new test method for demonstrating beta-lactamase activity among mycobacteria and nocardia. , 1973, Tubercle.

[34]  J. Kasík,et al.  Properties of β-lactamases produced by three species of mycobacteria , 1968 .

[35]  R. Knight,et al.  Mycobacterial penicillinase activity. , 1966, The American review of respiratory disease.